An authoritative database of FDA’s fast-tracked medical devices. STAT Reports blend data insights with qualitative observations on pivotal life sciences topics.

At STAT, our mission is to deliver trusted, tough-minded journalism on the business of making medicines, health tech, science, public health, hospitals, and insurance.

Our price covers the cost of daily coverage, two daily STAT+ newsletters, free access to exclusive subscriber only virtual events, discounts to STAT events and summits, and additional benefits.

Biotech STAT Staff ‘Remarkable’ drug results against an aggressive leukemia First Opinion Dorit R. Reiss RFK Jr.’s vaccine advisory panel is beset by incompetence, bias, and procedural chaos

Biotech Jason Mast Fulcrum study suggests improved efficacy for higher dose sickle cell pill Biotech STAT Staff ‘Remarkable’ drug results against an aggressive leukemia

STAT’s annual Monday evening event at JPM examines the political, social, and scientific forces reshaping health care in the year ahead.

Biotech news: Inside the discoveries, personalities, and deals driving drug development in general and biomedical engineering in particular. Sign up for The Readout newsletter to get the latest on ...

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Learn More. Cancel anytime. Interested in a group rate? Contact us.

STAT coverage and analysis of top pharmaceutical companies, from clinical trials to FDA approvals, from startups to Big Pharma mergers and acquisitions.

Nov 29, 2025 · Many of the experts who STAT spoke with believed that Prasad had written the memo with the express purpose that it would be leaked.